SBC Medical Group Holdings Incorporated (SBC) AI Stock Analysis

SBC Medical Group Holdings Incorporated provides comprehensive management and operational services to cosmetic treatment centers located in Japan, Vietnam, the United States, and Singapore. Its service portfolio includes advertising and social media marketing, staff recruitment and training, customer booking reservations, employee housing assistance, leasehold improvement, clinic design, and IT software solutions. SBC also manages customer loyalty programs, offers consulting services, and engages in franchising. In addition, it distributes medical equipment, devices, consumables, implants, and cosmetic skincare products to franchisee clinics. These clinics deliver surgical and non-surgical treatments ranging from rhinoplasty and liposuction to laser skin procedures.

Between FY2022 and FY2025, revenue posted a 3-year CAGR of -0.1%, moving from $174.2M in FY2022 to $193.5M in FY2023, $205.4M in FY2024, and declining 15.5% to $173.6M in FY2025. Despite top-line contraction in FY2025, net income rose to $51.0M from $46.6M in FY2024 and $6.3M in FY2022, expanding net margin from 3.6% in FY2022 to 29.4% in FY2025. Operating margin also improved to 38.9% in FY2025. For the trailing twelve months, revenue reached $175.2M with EPS of $0.47. In the latest quarter ended June 30, 2026, quarterly revenue grew 13.4% year-over-year, while quarterly earnings expanded by 338.9%.

As of June 30, 2026, SBC held $184.6M in cash and short-term investments alongside total debt of $48.2M, resulting in a net cash position of $136.4M. The company maintains a current ratio of 3.31 and a low debt-to-equity ratio of 0.18 on shareholders' equity of $263.8M. Operating cash flow reached $38.9M in FY2025, supporting free cash flow of $36.6M. Capital allocation in FY2025 included $2.4M in capital expenditures and $5.0M directed toward share buybacks.

At a share price of $5.16, SBC trades at a market capitalization of $530.7M and an enterprise value of $362.4M. Its trailing P/E of 11.0x and forward P/E of 9.3x compare to medians of 24.8x and 17.2x for US-listed Industrials peers. The company's EV/EBITDA stands at 4.6x, below the peer median of 13.9x, while its price-to-sales multiple is 3.0x versus 1.5x for peers. Over the past year, SBC generated a 23.7% return, outperforming the S&P 500 return of 16.8%.

Wall Street coverage includes 2 Strong Buy ratings and 1 Buy rating, with no Hold, Sell, or Strong Sell recommendations. The mean price target is $8.75, representing a 69.6% upside from the last close of $5.16. For the fiscal year ending December 31, 2026, consensus estimates project revenue of $191.0M and EPS of $0.46, representing an 8.0% drop in EPS. For the next fiscal year, 2 analysts expect revenue of $210.4M and EPS of $0.54. SBC has beaten EPS estimates in 3 of the last 4 quarters, with the next earnings release scheduled for November 13, 2026.

This page is an AI-written research summary of SBC Medical Group Holdings Incorporated (SBC). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: SBC income statement, SBC balance sheet, SBC key metrics, SBC analyst forecast, SBC chart. See the SBC stock overview for the latest quote and news.